Anji Pharma, a Boston-Shanghai startup, in-licensed China rights to pradigastat, a potential treatment for hyperlipoproteinemia currently in a Phase III trial, from Novartis. Hyperlipoproteinemia results from an inability to break down lipids or fats, specifically cholesterol and triglycerides. Anji paid Novartis $2 million upfront and will make additional milestone and royalty payments. Initially, Anji will conduct China trials for the candidate; it plans to eventually pursue additional indications. Anji is a genomically based drug discovery company with Shanghai clinical operations.
Source: China Biotoday
